As palliative care physicians become increasingly involved in the care of patients with amyotrophic lateral sclerosis (ALS), they will be asked to provide guidance regarding the use of supplements, diet, exercise, and other common preventive medicine interventions. Moreover, palliative care physicians have a crucial role assisting patients with ALS in addressing health care decisions to maximize quality of life and cope with a rapidly disabling disease. It is therefore important for palliative care physicians to be familiar with commonly encountered palliative care issues in ALS. This article provides an evidenced-based review of palliative care options not usually addressed in national and international ALS guidelines.
MillerRGJacksonCEKasarskisEJ. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology. Neurology. 2009;73(15):1227–1233. doi:10.1212/WNL.0b013e3181bc01a4.
2.
MillerRGJacksonCEKasarskisEJ. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology. Neurology. 2009;73(15):1218–1226. doi:10.1212/WNL.0b013e3181bc0141.
3.
EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis; AndersenPMAbrahamsSBorasioGD. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)—revised report of an EFNS task force. Eur J Neurol. 2012;19(3):360–375. doi:10.1111/j.1468-1331.2011.03501.x.
4.
KolarcikCLBowserR. Retinoid signaling alterations in amyotrophic lateral sclerosis. Am J Neurodegener Dis. 2012;1(2):130–145.
5.
CrochemoreCVirgiliMBonamassaB. Long-term dietary administration of valproic acid does not affect, while retinoic acid decreases, the lifespan of G93A mice, a model for amyotrophic lateral sclerosis. Muscle Nerve. 2009;39(4):548–552. doi:10.1002/mus.21260.
6.
MattsonMPSheaTB. Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci. 2003;26(3):137–146. doi:10.1016/S0166-2236(03)00032-8.
7.
ZoccolellaSSimoneILLambertiP. Elevated plasma homocysteine levels in patients with amyotrophic lateral sclerosis. Neurology. 2008;70(3):222–225. doi:10.1212/01.wnl.0000297193.53986.6f.
8.
ValentinoFBivonaGButeraD. Elevated cerebrospinal fluid and plasma homocysteine levels in ALS. Eur J Neurol. 2010;17(1):84–89. doi:10.1111/j.1468-1331.2009.02752.x.
9.
ZhangXChenSLiLWangQLeW. Folic acid protects motor neurons against the increased homocysteine, inflammation and apoptosis in SOD1 G93A transgenic mice. Neuropharmacology. 2008;54(7):1112–1119. doi:10.1016/j.neuropharm.2008.02.020.
10.
HemendingerRAArmstrongEJIIIBrooksBR. Methyl vitamin B12 but not methylfolate rescues a motor neuron-like cell line from homocysteine-mediated cell death. Toxicol Appl Pharmacol. 2011;251(3):217–225. doi:10.1016/j.taap.2011.01.003.
11.
SongLGaoYZhangXLeW. Galactooligosaccharide improves the animal survival and alleviates motor neuron death in SOD1G93A mouse model of amyotrophic lateral sclerosis. Neuroscience. 2013;246:281–290. doi:10.1016/j.neuroscience.2013.05.002.
12.
PoloniMPatriniCRocchelliBRindiG. Thiamin monophosphate in the CSF of patients with amyotrophic lateral sclerosis. Arch Neurol. 1982;39(8):507–509.
13.
PoloniMMazzarelloPPatriniCPinelliP. Inversion of T/TMP ratio in ALS: a specific finding?Ital J Neurol Sci. 1986;7(3):333–335.
14.
MogesHVasconcelosOMCampbellWW. Light therapy and supplementary riboflavin in the SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis (FALS). Lasers Surg Med. 2009;41(1):52–59. doi:10.1002/lsm.20732.
15.
FitzgeraldKCO’ReillyEJFondellE. Intakes of vitamin C and carotenoids and risk of amyotrophic lateral sclerosis: pooled results from 5 cohort studies. Ann Neurol. 2013;73(2):236–245. doi:10.1002/ana.23820.
16.
KaramCScelsaSN. Can vitamin D delay the progression of ALS?Med Hypotheses. 2011;76(5):643–645. doi:10.1016/j.mehy.2011.01.021.
17.
GianforcaroAHamadehMJ. Dietary vitamin D3 supplementation at 10x the adequate intake improves functional capacity in the G93A transgenic mouse model of ALS, a pilot study. CNS Neurosci Ther. 2012;18(7):547–557. doi:10.1111/j.1755-5949.2012.00316.x.
18.
GianforcaroASolomonJAHamadehMJ. Vitamin D(3) at 50× AI attenuates the decline in paw grip endurance, but not disease outcomes, in the G93A mouse model of ALS, and is toxic in females. PLoS One. 2013;8(2):e30243. doi:10.1371/journal.pone.0030243.
19.
SolomonJAGianforcaroAHamadehMJ. Vitamin D3 deficiency differentially affects functional and disease outcomes in the G93A mouse model of amyotrophic lateral sclerosis. PLoS One. 2011;6(12):e29354. doi:10.1371/journal.pone.0029354.
20.
KaramCBarrettMJImperatoTMacGowanDJScelsaS. Vitamin D deficiency and its supplementation in patients with amyotrophic lateral sclerosis. J Clin Neurosci. 2013;20(11):1550–1553. doi:10.1016/j.jocn.2013.01.011.
GurneyMECuttingFBZhaiP. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol. 1996;39(2):147–157. doi:10.1002/ana.410390203.
23.
DesnuelleCDibMGarrelCFavierA.A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol study group. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001;2(1):9–18.
24.
GrafMEckerDHorowskiR. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study. J Neural Transm. 2005;112(5):649–660. doi:10.1007/s00702-004-0220-1.
25.
WangHO’ReillyEJWeisskopfMG. Vitamin E intake and risk of amyotrophic lateral sclerosis: a pooled analysis of data from 5 prospective cohort studies. Am J Epidemiol. 2011;173(6):595–602. doi:10.1093/aje/kwq416; 10.1093/aje/kwq416.
26.
CalderPCYaqoobP. Omega-3 polyunsaturated fatty acids and human health outcomes. Biofactors. 2009;35(3):266–272. doi:10.1002/biof.42; 10.1002/biof.42.
YipPKPizzasegolaCGladmanS. The omega-3 fatty acid eicosapentaenoic acid accelerates disease progression in a model of amyotrophic lateral sclerosis. PLoS One. 2013;8(4):e61626. doi:10.1371/journal.pone.0061626.
29.
KiraYNishikawaMOchiASatoEInoueM. l-Carnitine suppresses the onset of neuromuscular degeneration and increases the life span of mice with familial amyotrophic lateral sclerosis. Brain Res. 2006;1070(1):206–214. doi:10.1016/j.brainres.2005.11.052.
30.
BeghiEPupilloEBonitoV. Randomized double-blind placebo-controlled trial of acetyl-l-carnitine for ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(5-6):397–405. doi:10.3109/21678421.2013.764568.
31.
FerranteKLShefnerJZhangH. Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS. Neurology. 2005;65(11):1834–1836. doi:10.1212/01.wnl.0000187070.35365.d7.
32.
KaufmannPThompsonJLLevyG. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann Neurol. 2009;66(2):235–244. doi:10.1002/ana.21743.
33.
KlivenyiPFerranteRJMatthewsRT. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med. 1999;5(3):347–350. doi:10.1038/6568.
34.
RosenfeldJKingRMJacksonCE. Creatine monohydrate in ALS: effects on strength, fatigue, respiratory status and ALSFRS. Amyotroph Lateral Scler. 2008;9(5):266–272. doi:10.1080/17482960802028890.
35.
GroeneveldGJVeldinkJHvan der TweelI. A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol. 2003;53(4):437–445. doi:10.1002/ana.10554.
AtassiNRataiEMGreenblattDJ. A phase I, pharmacokinetic, dosage escalation study of creatine monohydrate in subjects with amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010;11(6):508–513. doi:10.3109/17482961003797130.
38.
Nutritional status of patients with amyotrophic lateral sclerosis: relation to the proximity of death. Dysphagia. 1997;12(3):174–175.
39.
SanchoJServeraEChinerE. Noninvasive respiratory muscle aids during PEG placement in ALS patients with severe ventilatory impairment. J Neurol Sci. 2010;297(1-2):55–59. doi:10.1016/j.jns.2010.06.022.
40.
DesportJCPreuxPMTruongTCVallatJMSautereauDCouratierP. Nutritional status is a prognostic factor for survival in ALS patients. Neurology. 1999;53(5):1059–1063.
41.
NgoSTSteynFJMcCombePA. Body mass index and dietary intervention: implications for prognosis of amyotrophic lateral sclerosis. J Neurol Sci. 2014;340(1-2):5–12. doi:10.1016/j.jns.2014.02.035.
42.
PaganoniSDengJJaffaMCudkowiczMEWillsAM. Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis. Muscle Nerve. 2011;44(1):20–24. doi:10.1002/mus.22114.
43.
WillsAMHubbardJMacklinEA. Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet. 2014;383(9934):2065–2072. doi:10.1016/S0140-6736(14)60222-1.
CarterGTAboodMEAggarwalSKWeissMD. Cannabis and amyotrophic lateral sclerosis: hypothetical and practical applications, and a call for clinical trials. Am J Hosp Palliat Care. 2010;27(5):347–356. doi:10.1177/1049909110369531.
46.
WeydtPHongSWittingAMollerTStellaNKliotM. Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005;6(3):182–184. doi:10.1080/14660820510030149.
47.
AmtmannDWeydtPJohnsonKLJensenMPCarterGT. Survey of cannabis use in patients with amyotrophic lateral sclerosis. Am J Hosp Palliat Care. 2004;21(2):95–104.
48.
DroryVEBronipolskyTArtamonovINefussyB. Influence of statins treatment on survival in patients with amyotrophic lateral sclerosis. J Neurol Sci. 2008;273(1-2):81–83. doi:10.1016/j.jns.2008.06.022.
49.
ZinmanLSadeghiRGawelMPattonDKissA. Are statin medications safe in patients with ALS?Amyotroph Lateral Scler. 2008;9(4):223–228. doi:10.1080/17482960802031092.
50.
SorensenHTRiisAHLashTLPedersenL. Statin use and risk of amyotrophic lateral sclerosis and other motor neuron disorders. Circ Cardiovasc Qual Outcomes. 2010;3(4):413–417. doi:10.1161/CIRCOUTCOMES.110.936278.
51.
GolombBAKwonEKKoperskiSEvansMA. Amyotrophic lateral sclerosis-like conditions in possible association with cholesterol-lowering drugs: an analysis of patient reports to the University of California, San Diego (UCSD) statin effects study. Drug Saf. 2009;32(8):649–661. doi:10.2165/00002018-200932080-00004.
52.
DupuisLCorciaPFerganiA. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology. 2008;70(13):1004–1009. doi:10.1212/01.wnl.0000285080.70324.27.
53.
ZhengZShengLShangH. Statins and amyotrophic lateral sclerosis: a systematic review and meta-analysis. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(4):241–245. doi:10.3109/21678421.2012.732078.
54.
GordonPHMooreDHMillerRG. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol. 2007;6(12):1045–1053. doi:10.1016/S1474-4422(07)70270-3.
55.
LeighPNMeiningerVBensimonGCudkowiczMRobberechtW. Minocycline for patients with ALS. Lancet Neurol. 2008;7(2):119–120; author reply 120–121. doi:10.1016/S1474-4422(08)70006-1.
56.
AshworthNLSatkunamLEDeforgeD. Treatment for spasticity in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2012;2:CD004156. doi:10.1002/14651858.CD004156.pub4.
57.
SquiresNHumberstoneMWillsAArthurA. The use of botulinum toxin injections to manage drooling in amyotrophic lateral sclerosis/motor neurone disease: a systematic review [published online May 22, 2014]. Dysphagia. 2014. doi:10.1007/s00455-014-9535-8.
58.
AssoulineALevyAAbdelnour-MalletM. Radiation therapy for hypersalivation: a prospective study in 50 amyotrophic lateral sclerosis patients. Int J Radiat Oncol Biol Phys. 2014;88(3):589–595. doi:10.1016/j.ijrobp.2013.11.230.
59.
McKelveyMEvansDLKawaiNBeukelmanD. Communication styles of persons with ALS as recounted by surviving partners. Augment Altern Commun. 2012;28(4):232–242. doi:10.3109/07434618.2012.737023.
60.
HwangCSWengHHWangLFTsaiCHChangHT. An eye-tracking assistive device improves the quality of life for ALS patients and reduces the caregivers’ burden. J Mot Behav. 2014;46(4):233–238. doi:10.1080/00222895.2014.891970.
61.
OlivieriCCastioniCALivigniS. Non-invasive ventilation after surgery in amyotrophic lateral sclerosis. Acta Neurol Scand. 2013. doi:10.1111/ane.12187.
62.
OndersRPCarlinAMElmoMSivashankaranSKatirjiBSchilzR. Amyotrophic lateral sclerosis: the midwestern surgical experience with the diaphragm pacing stimulation system shows that general anesthesia can be safely performed. Am J Surg. 2009;197(3):386–390. doi:10.1016/j.amjsurg.2008.11.008.
63.
PrabhakarAOwenCPKayeAD. Anesthetic management of the patient with amyotrophic lateral sclerosis. J Anesth. 2013;27(6):909–918. doi:10.1007/s00540-013-1644-2.
64.
BrambrinkAMKirschJR. Perioperative care of patients with neuromuscular disease and dysfunction. Anesthesiol Clin. 2007;25(3):483–509, viii–ix. doi:10.1016/j.anclin.2007.05.005.
65.
FiacchinoFGemmaMBricchiMGiombiniSRegiB. Sensitivity to curare in patients with upper and lower motor neurone dysfunction. Anaesthesia. 1991;46(11):980–982.
66.
KelsakaEKarakayaDZenginEC. Use of sugammadex in a patient with amyotrophic lateral sclerosis. Med Princ Pract. 2013;22(3):304–306. doi:10.1159/000343168.
67.
WachiMUeharaKFujinakaWTakatoriMTadaK. Use of sugammadex in a patient with amyotrophic lateral sclerosis. Masui. 2011;60(12):1408–1410.
68.
HobaikaABNevesBS. Combined spinal-epidural block in a patient with amylotrophic lateral sclerosis: a case report. Rev Bras Anesthesiol. 2009;59(2):206–209.
69.
PintoSSwashMde CarvalhoM. Does surgery accelerate progression of amyotrophic lateral sclerosis?J Neurol Neurosurg Psychiatry. 2014;85(6):643–646. doi:10.1136/jnnp-2013-305770.
70.
GayPCEdmondsLC. Severe hypercapnia after low-flow oxygen therapy in patients with neuromuscular disease and diaphragmatic dysfunction. Mayo Clin Proc. 1995;70(4):327–330. doi:S0025-6196(11)63410-1.
71.
JacksonCERosenfeldJMooreDH. A preliminary evaluation of a prospective study of pulmonary function studies and symptoms of hypoventilation in ALS/MND patients. J Neurol Sci. 2001;191(1-2):75–78. doi:S0022510X01006177.
72.
BourkeSCTomlinsonMWilliamsTLBullockREShawPJGibsonGJ. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol. 2006;5(2):140–147. doi:S1474-4422(05)70326-4.
73.
KleopaKAShermanMNealBRomanoGJHeiman-PattersonT. Bipap improves survival and rate of pulmonary function decline in patients with ALS. J Neurol Sci. 1999;164(1):82–88. doi:S0022-510X(99)00045-3.
74.
AboussouanLSKhanSUBanerjeeMArroligaACMitsumotoH. Objective measures of the efficacy of noninvasive positive-pressure ventilation in amyotrophic lateral sclerosis. Muscle Nerve. 2001;24(3):403–409. doi:10.1002/1097-4598(200103)24:3<403::AID-MUS1013>3.0.CO;2-3.
75.
PizzimentiAAragonaMOnestiEInghilleriM. Depression, pain and quality of life in patients with amyotrophic lateral sclerosis: a cross-sectional study. Funct Neurol. 2013;28(2):115–119. doi:10.11138/FNeur/2013.28.2.115.
76.
PagniniFLunettaCBanfiP. Pain in amyotrophic lateral sclerosis: a psychological perspective. Neurol Sci. 2012;33(5):1193–1196. doi:10.1007/s10072-011-0888-6.
